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Aim To evaluate the impact of left ventricular ejection fraction (LVEF) on 3-year outcomes in patients with left main
coronary artery disease (LMCAD) undergoing percutaneous coronary intervention (PCI) or coronary artery bypass
grafting (CABG) in the EXCEL trial.
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Methods
and results
The EXCEL trial randomized patients with LMCAD to PCI with everolimus-eluting stents (n = 948) or CABG
(n = 957). Among 1804 patients with known baseline LVEF, 74 (4.1%) had LVEF <40% [heart failure with reduced
ejection fraction (HFrEF)], 152 (8.4%) LVEF 40–49% [heart failure with mid-range ejection fraction (HFmrEF)] and
1578 (87.5%) LVEF ≥50% (heart failure with preserved ejection fraction). Patients with HFrEF vs. HFmrEF vs.
preserved LVEF experienced a longer postoperative hospital stay (9.0 vs. 7.0 vs. 6.0 days, P = 0.02) with greater
peri-procedural complications after CABG, while hospital stay after PCI was unaffected by LVEF (1.5 vs. 2.0 vs.
1.0 days, P = 0.20). The composite primary endpoint of death, stroke, or myocardial infarction at 3 years was 29.3%
(PCI) vs. 27.6% (CABG) in patients with HFrEF, 16.2% vs. 15.0% in patients with HFmrEF, and 14.5% vs. 14.6% in
those with preserved LVEF, respectively (Pinteraction = 0.90). Smoothing spline analysis demonstrated that the 3-year
risk of all-cause death increased when LVEF decreased, both in patients undergoing CABG and PCI.
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Conclusion In the EXCEL trial, the composite rate of death, stroke or myocardial infarction at 3 years was significantly higher
in patients with HFrEF compared with HFmrEF or preserved LVEF, driven by an increased rate of all-cause death.
No significant differences after PCI vs. CABG were observed among patients with HFrEF, HFmrEF and preserved
LVEF. Longer-term follow-up could provide important insights on differences in clinical outcomes that might emerge
over time.
Clinical Trial Registration: ClinicalTrials.gov ID NCT01205776.
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Introduction
Coronary artery bypass surgery is generally recommended for
patients with extensive multivessel coronary artery disease
(CAD) and severely impaired left ventricular ejection fraction
(LVEF) (<35%).1,2 However, whether coronary artery bypass
grafting (CABG) or percutaneous coronary intervention (PCI) is
preferred in patients with left main CAD (LMCAD) and impaired
LVEF (<50%) is unclear.Whereas randomized trials of patients with
impaired LVEF undergoing CABG vs. medical therapy have been
performed,3 most trials comparing PCI with CABG have excluded
patients with severely impaired LVEF (≤35%). Insights related to
myocardial revascularization in patients with impaired LVEF are
thus mainly limited to observational studies. A recent systematic
review of mainly observational studies (n = 16191), compared
myocardial revascularization with medical therapy and reported an
overall survival benefit of CABG over PCI in 8782 patients with
LVEF ≤40% [hazard ratio (HR) 0.82; 95% confidence interval (CI)
0.75–0.90].4 However, the results varied widely between the indi-
vidual studies (I2 = 47%), possibly in part because follow-up ranged
from 12–180months. Moreover, only a limited number of patients
with LMCAD and impaired LVEF was included in the analysis.
In the EXCEL (Evaluation of XIENCE Versus Coronary Artery
Bypass Surgery for Effectiveness of Left Main Revascularization)
trial, PCI with drug-eluting stents was shown to be an acceptable
alternative to CABG in selected patients with LMCAD at 3-year
follow-up.5–7 The current pre-specified EXCEL sub-study aims to
estimate the impact of LVEF, defined according to the European
Society of Cardiology heart failure terminology,8 on 3-year out-
comes and evaluates differences in treatment effect of PCI with
everolimus-eluting stents vs. CABG according to LVEF in patients
with LMCAD in the EXCEL trial.
Methods
Study design
The design of the EXCEL trial and the main outcomes have been
reported previously.9,10 In brief, 1905 patients with LMCAD and a
site-determined SYNTAX score of ≤32 were randomized to PCI
with everolimus-eluting stents (n = 948) and CABG (n = 957). Among
those, baseline data on LVEF were available for 1804 patients (94.7%)
and were assessed within 14 days after randomization. In 226 out
of 1804 patients (12.5%) LVEF was <50%. These 226 patients were
classified according to the European Society of Cardiology heart failure
terminology; heart failure with reduced ejection fraction (HFrEF; LVEF
<40%) and heart failure with mid-range ejection fraction (HFmrEF;
LVEF 40–49%). The HFrEF group consisted of 74 patients, and of
those 43 were randomized to PCI and 31 to CABG. There were 152
patients in the HFmrEF group, of which 68 were randomized to PCI
and 84 to CABG. LVEF was preserved (≥50%) in 1578 out of 1804
patients (87.5%), of whom 782 were randomized to PCI and 796 to
CABG. The aim of the present pre-specified analysis was to evaluate
the association of LVEF on 3-year clinical outcomes among patients
with LMCAD undergoing PCI or CABG.
All patients reached 3-year follow-up at the time of this post-hoc
analysis. An independent clinical events committee monitored and
adjudicated adverse events. Informed consent was signed by all patients ..
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.. prior to randomization. The EXCEL trial complies with the Declaration
of Helsinki and is registered at ClinicalTrials.gov (NCT01205776).
Endpoints
The primary endpoint consisted of the composite rate of all-cause
death, stroke, or myocardial infarction (MI),11 at 3 years in subgroups
of patients with HFrEF, HFmrEF and preserved LVEF, randomized
to either PCI or CABG. Secondary powered endpoints included
the primary endpoint measure at 30 days and the composite rate of
all-cause death, stroke, MI, or ischaemia-driven revascularization at
3 years in subgroup of patients with HFrEF, HFmrEF and preserved
LVEF, randomized to PCI or CABG. Additional endpoints consisted of
the individual components of the primary and secondary endpoints at
3 years and 30 days.9,10
Statistical analyses
All analyses were performed according to the intention-to-treat princi-
ple. Discrete variables were expressed as percentages with frequencies
and compared with the 𝜒2 test or Fisher exact test when the expected
frequency in any cell was <5. Continuous variables were summarized
as mean± standard deviation and were compared by independent
samples t-test if normally distributed, or the Wilcoxon rank-sum
test when non-normally distributed. Event rates up to 3 years were
estimated according to the Kaplan–Meier method, and differences
between baseline LVEF subgroups (HFrEF, HFmrEF, and preserved),and
PCI vs. CABG, were assessed using the log-rank test. Any differences
in baseline characteristics between subgroups of patients with HFrEF,
HFmrEF and preserved LVEF were adjusted using a multivariable Cox
proportional hazard model, correcting for pre-specified important
clinical and statistical variables. The association of LVEF as a contin-
uous variable on the 3-year hazard of all-cause death was analysed
by smoothing spline analysis with a linear Cox proportional hazards
regression model. Baseline characteristics of patients with and without
known baseline LVEF were compared to check for potential attrition
bias. All reported P-values are 2-sided, and P< 0.05 was considered
to be statistically significant. Statistical analyses were performed with
SAS version 9.4 (SAS Institute, Cary, NC, USA).
Results
Baseline characteristics
The baseline characteristics of the overall cohort of patients
classified as HFrEF (n = 74), HFmrEF (n = 152) and those with
preserved LVEF (n = 1578) are provided in Table 1. LVEF was
assessed by cardiac ultrasound in 1051 patients (58.3%) and
contrast left ventriculography in 715 patients (39.6%). Magnetic
resonance or nuclear imaging were used in 38 patients (2.1%).
Mean LVEF was 31.6% vs. 43.6% vs. 59.6% in patients with HFrEF
vs. HFmrEF vs. preserved LVEF, respectively (P = <0.001). Patients
with HFrEF and HFmrEF vs. preserved LVEF had a significantly
worse cardiovascular risk profile and had a higher pre-operative
risk reflected by increased predicted risk of mortality STS risk
scores (1.11 vs. 0.96 vs. 0.86, respectively; P = 0.02). More
patients with HFrEF had a high SYNTAX score (≥33, core labo-
ratory analysis) compared to those with HFmrEF and preserved
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Baseline characteristics according to left ventricular ejection fraction
Characteristics % (n/N) LVEF <40%
(HFrEF) (n = 74)
LVEF 40–49%
(HFmrEF) (n = 152)
Preserved LVEF ≥50%
(n = 1578)
P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age (years) 67.0 ± 9.3 66.7 ± 9.3 65.9 ± 9.6 0.42
Female sex 21/74 (28.4) 20/152 (13.2) 380/1578 (24.1) 0.006
LVEF (%) 31.6 ± 4.2 43.6 ± 2.6 59.6 ± 6.6 <0.001
CAD risk factors
Hypertensiona 54/74 (73.0) 112/152 (73.7) 1169/1578 (74.1) 0.97
Hyperlipidaemia 45/74 (60.8) 100/151 (66.2) 1116/1577 (70.8) 0.11
Diabetes mellitusa 24/74 (32.4) 57/152 (37.5) 449/1578 (28.5) 0.05
Current or former smoker 53/74 (71.6) 103/151 (68.2) 962/1566 (61.4) 0.06
Family history of CAD 45/64 (70.3) 92/125 (73.6) 868/1323 (65.6) 0.16
NYHA class, known 23/74 (31.1) 23/152 (15.1) 73/1573 (4.6) <0.001
I 4/74 (5.4) 3/152 (2.0) 16/1573 (1.0) 0.003
II 6/74 (8.1) 15/152 (9.9) 33/1573 (2.1) <0.001
III 12/74 (16.2) 5/152 (3.3) 23/1573 (1.5) <0.001
IV 1/74 (1.4) 0/152 (0.0) 2/1573 (0.1) 0.04
Pre-operative risk factors
History of stroke 6/74 (8.1) 8/152 (5.3) 50/1577 (3.2) 0.04
History of TIA 2/74 (2.7) 4/151 (2.6) 47/1569 (3.0) 0.96
Recent myocardial infarctionb 18/74 (24.3) 34/151 (22.5) 219/1574 (13.9) 0.001
Chronic kidney diseasec 24/73 (32.9) 39/149 (26.2) 231/1550 (14.9) <0.001
Dialysis 0/74 (0.0) 2/152 (1.3) 3/1578 (0.2) 0.04
Peripheral vascular disease 14/72 (19.4) 23/152 (15.1) 133/1572 (8.5) 0.004
Chronic obstructive pulmonary disease 14/74 (18.9) 17/152 (11.2) 113/1575 (7.2) 0.004
History of carotid artery disease 13/74 (17.6) 12/150 (8.0) 125/1574 (7.9) 0.01
Body mass index (kg/m2) 28.9 ± 6.4 28.7 ± 4.9 28.7 ± 4.9 0.93
< 20: cachectic 2/74 (2.7) 2/152 (1.3) 24/1578 (1.52) 0.52
> 30: obese 25/74 (33.8) 47/152 (30.9) 514/1578 (32.6) 0.85
History of anaemiad 8/74 (10.8) 23/152 (15.1) 146/1572 (9.3) 0.07
Lesions per patient 2.7 ±1.5 (42) 2.9 ±1.5 (66) 2.5 ±1.3 (773) 0.051
Diffuse disease or small vessels 4/73 (5.5) 18/146 (12.3) 85/1555 (5.5) 0.004
Critical pre-operative statee STS risk scores
PROM score 1.11 ±1.0 0.96 ± 0.93 0.86 ± 0.78 0.02
Stroke score 0.97 ± 0.82 0.82 ± 0.61 0.75 ± 0.56 0.004
Reop. score 4.00 ±1.63 3.64 ± 1.41 3.51 ±1.34 0.007
SYNTAX score (site-assessed) 21.0 ± 5.7 22.4 ± 5.7 20.4 ± 6.2 (1576) 0.004
Low (≤22) 41/74 (55.4) 77/152 (50.7) 967/1576 (61.4) 0.03
Intermediate (23–32) 33/74 (44.6) 75/152 (49.3) 609/1576 (38.6) 0.03
High (≥33) 0/74 (0.0) 0/152 (0.0) 0/1576 (0.0) –
SYNTAX score (core laboratory-assessed) 28.4± 9.7 27.6± 9.2 26.3± 9.3 (1526) 0.06
Low (≤22) 24/72 (33.3) 37/144 (25.7) 563/1526 (36.9) 0.03
Intermediate (23–32) 21/72 (29.2) 76/144 (52.8) 600/1526 (39.3) 0.001
High (≥33) 27/72 (37.5) 31/144 (21.5) 363/1526 (23.8) 0.021
Values are mean± standard deviation, or n (%).
CAD, coronary artery disease; HFmrEF, heart failure with mid-range ejection fraction; HFrEF, heart failure with reduced ejection fraction; LVEF, left ventricular ejection
fraction; NYHA, New York Heart Association heart failure classification; PROM, Predicted Risk Of Mortality; STS, Society of Thoracic Surgeons; SYNTAX, Synergy between
Percutaneous Coronary Intervention with Taxus and Cardiac Surgery; TIA, transient ischaemic attack.
aMedically treated.
bWithin 7 days of randomization.
cEstimated glomerular filtration rate < 60mL/min.
dWorld Health Organization criteria: Hematocrit <13 g/dL (male) and<12 g/dL (female).
eVentricular tachycardia, ventricular fibrillation, or aborted sudden death; preoperative cardiac massage; preoperative ventilation before anesthetic room; preoperative
inotropes or intra-aortic balloon pump; preoperative acute renal failure (anuria or oliguria <10 mL/h).
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 Procedural characteristics and discharge medication according to left ventricular ejection fraction and
revascularization assignment
CABG (n = 911) PCI (n = 893)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
LVEF <40%
(HFrEF)
(n = 31)
LVEF 40–49%
(HFmrEF)
(n = 84)
Preserved
LVEF ≥50%
(n = 796)
P-value LVEF <40%
(HFrEF)
(n = 43)
LVEF 40–49%
(HFmrEF)
(n = 68)
Preserved
LVEF ≥50%
(n = 782)
P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Assigned treatment received 28/31 (90.3) 81/84 (96.4) 774/796 (97.2) 0.098 42/43 (97.7) 66/68 (97.1) 773/782 (98.9) 0.22
Procedure durationa (min) 231 [215–305] 239 [200–291] 235 [195–280] 0.39 66 [51–101] 83 [65–109] 73 [51–106] 0.59
Bypass time (min) 80 [59–87] 73 [62–94] 74 [57–97] 0.77 – – – –
Off-pump CABG 10/28 (35.7) 23/81 (28.4) 225/774 (29.1) 0.74 – – – –
BITAs used 4/28 (14.3) 25/80 (31.3) 219/771 (28.4) 0.22 – – – –
No. of distal anastomoses 2.5 ± 0.6 2.6 ± 0.8 2.7 ± 0.8 0.83 – – –
No. of grafts used 3.0 [2.0–3.0] 2.0 [2.0–3.0] 2.0 [2.0–3.0] 0.32 – – – –
No. of stents implanted – – – – 2.0 [1.0–4.0] 3.0 [2.0–3.0] 2.0 [1.0–3.0] 0.004
Total stent length (mm) – – – – 35.0 [26.0–76.0] 52.0 [30.0–84.0] 38.0 [23.0–61.0] 0.003
Intubation > 48 h 2/29 (6.9) 5/82 (6.1) 21/787 (2.7) 0.12 1/42 (2.4) 0/67 (0.0) 3/778 (0.4) 0.15
Renal failureb 4/29 (13.8) 4/82 (4.9) 15/787 (1.9) 0.001 2/42 (4.8) 0/67 (0.0) 4/778 (0.5) 0.004
Major arrhythmia 9/29 (31.0) 17/82 (20.7) 108/787 (13.7) 0.011 1/42 (2.4) 1/67 (1.5) 14/778 (1.8) 0.94
Post-operative hospital stay (days) 9.0 [5.0–13.0] 7.0 [5.0–10.0] 6.0 [5.0–9.0] 0.02 1.5 [1.0–3.0] 2.0 [1.0–3.0] 1.0 [1.0–2.0] 0.20
Discharge medications
Aspirin 26/27 (96.3) 79/79 (100.0) 752/760 (98.9) 0.26 42/42 (100.0) 66/66 (100.0) 760/766 (99.2) 0.65
P2Y12 inhibitor 7/27 (25.9) 22/79 (27.8) 259/765 (33.9) 0.40 42/42 (100.0) 65/66 (98.5) 754/769 (98.0) 0.64
DAPT 7/27 (25.9) 22/79 (27.8) 254/765 (33.2) 0.48 42/42 (100.0) 65/66 (98.5) 748/769 (97.3) 0.47
Statin 25/27 (92.6) 70/79 (88.6) 709/765 (92.7) 0.43 40/42 (95.2) 66/66 (100.0) 741/769 (96.4) 0.26
Beta-blocker 26/27 (96.3) 74/79 (93.7) 704/765 (92.0) 0.64 40/42 (95.2) 57/66 (86.4) 634/769 (82.4) 0.08
ACE-inhibitor or ARB 12/27 (44.4) 37/79 (46.8) 311/765 (40.7) 0.54 26/42 (61.9) 39/66 (59.1) 428/769 (55.7) 0.65
Calcium-channel blockers 0/27 (0.0) 9/79 (11.4) 53/765 (6.9) 0.12 0/42 (0.0) 1/66 (1.5) 48/769 (6.2) 0.07
Diuretics 7/27 (25.9) 18/79 (22.8) 185/765 (24.2) 0.94 2/42 (4.8) 2/66 (3.0) 26/769 (3.4) 0.88
Values are n (%), median [interquartile range], or mean± standard deviation.
ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blockers; BITA, bilateral internal thoracic artery; CABG, coronary artery bypass grafting; DAPT, dual antiplatelet therapy; HFmrEF, heart
failure with mid-range ejection fraction; HFrEF, heart failure with reduced ejection fraction; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention.
aTime from start of anaesthesia to procedure end (e.g. for CABG this is the time of skin closure).
bSerum creatinine increase by ≥1 mg/dL from baseline or need for dialysis.
LVEF (37.5% vs. 21.5% vs. 23.8%, respectively; P = 0.02). The
specific cardiovascular risk profile of patients with HFrEF, HFmrEF
and preserved LVEF randomized to PCI vs. CABG are reported in
online supplementary Table S1. No differences between baseline
characteristics among those patients with vs. those without known
baseline LVEF were identified (online supplementary Table S2).
Procedural characteristics
Surgical techniques used for CABG were similar among patients
with HFrEF, HFmrEF and preserved LVEF (Table 2). Off-pump
CABG was performed in 35.7% of patients (n = 10/28) with
HFrEF, in 28.4% of patients (n = 23/81) with HFmrEF and in 29.1%
of patients (n = 225/774) with preserved LVEF. Bilateral internal
thoracic arteries were used less frequently in patients with HFrEF
(14.3%; n = 4/28) vs. in those with HFmrEF (31.3%; n = 25/80)
and preserved LVEF (28.4%; n = 219/771). The number of distal
anastomoses did not differ among patients with HFrEF, HFmrEF
and preserved LVEF. The duration of the PCI procedure was similar
among patients with HFrEF, HFmrEF and preserved LVEF (Table 2),
while the number of implanted stents and the total stent length
differed significantly between patients with HFrEF, HFmrEF and
preserved LVEF.
After CABG, patients with HFrEF vs. HFmrEF vs. preserved
LVEF had a longer post-operative hospital stay (median 9.0 vs. 7.0
vs. 6.0, P = 0.02), and more often experienced renal failure and .
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. arrhythmias (Table 2). Following PCI, no differences were identified
in hospital stay, however patients with HFrEF more often had
post-operative renal failure. No statistical differences were noted
in medical treatment at the time of discharge after CABG or PCI
according to LVEF status.
Thirty-day outcomes
Overall, the event rates for the primary endpoint, as well as for the
individual endpoints, were relatively low. The composite endpoint
of death, stroke, or MI occurred more frequently in patients with
preserved LVEF that underwent CABG compared with those that
underwent PCI (7.9% vs. 5.1%; HR 0.65, 95% CI 0.44–0.97; online
supplementary Table S3). No treatment-by-subgroup interaction
was identified between LVEF status (HFrEF, HFmrEF and preserved
LVEF) and revascularization strategy (PCI vs. CABG) among any of
the clinical endpoints.
Three-year outcomes
The composite of death, stroke, or MI was 28.3% vs. 15.7% vs.
14.5% according to HFrEF, HFmrEF and preserved LVEF status
(P = 0.02) (Figure 1A). All-cause death occurred in 19.5% vs. 9.6%
vs. 6.2%, respectively (P< 0.001) (Figure 1B). Smoothing spline
analysis showed a gradually increasing risk of all-cause death with
decreasing LVEF below 50% after PCI (Figure 2) (HR 1.15, 95% CI
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Three-year clinical endpoints in the overall cohort of patients with heart failure with reduced, mid-range and preserved left
ventricular ejection fraction. Kaplan–Meier estimates of (A) the composite primary endpoint of all-cause death, stroke, or myocardial infarction
(MI) and individual components of the composite primary endpoint; all-cause death (B), MI (C) and stroke (D) in pre-specified subgroups of
patients with heart failure with reduced, mid-range (orange curve) and preserved left ventricular ejection fraction. P-values were generated by
the log-rank test. CI, confidence interval; HR, hazard ratio.
0.95–1.39) and CABG (HR 1.90, 95% CI 1.05–3.43). Patients with
HFrEF, HFmrEF and preserved LVEF had comparable rates of stroke
and MI (Figure 1C and D).
The rates of the 3-year composite primary endpoint were
similar between PCI and CABG across groups of patients with
HFrEF (29.3% after PCI vs. 27.6% after CABG: P = 0.90), those
with HFmrEF (16.2% vs. 15.0%; P = 0.93) and preserved LVEF
(14.5% vs. 14.6%; P = 0.95) (Table 3 and Figure 3). The indi-
vidual rates of all-cause death, stroke, MI and ischaemia-driven
revascularization were not statistically different between PCI and
CABG in patients with HFrEF or HFmrEF. Any repeat revas-
cularization occurred more often after PCI vs. CABG in those
patients with preserved LVEF (HR 1.68, 95% CI 1.22–2.30), driven
by increased rates of ischaemia-driven revascularization. No
treatment-by-subgroup interaction existed according to baseline
LVEF and revascularization strategy. Adjusted outcomes from the .
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.. full multivariable adjusted Cox proportional hazard model were
similar to unadjusted outcomes (Table 3).
Discussion
In the current pre-specified sub-study from the EXEL trial, the
largest randomized study to date comparing PCI vs. CABG in
selected patients with LMCAD, the composite rate of death,
stroke, or MI at 3-year follow-up was significantly higher in
patients with impaired (<50%; n = 74) vs. preserved LVEF (≥50%;
n = 1730), driven by an increased rate of all-cause death in those
with HFrEF (n = 74, LVEF<40%). Mortality furthermore progres-
sively increased with decreasing LVEF. Nonetheless, baseline LVEF
did not influence the relative 30-day or 3-year treatment out-
comes in patients with LMCAD randomly allocated to PCI vs.
CABG. Since data on the influence of HFrEF and HFmrEF on
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 3 Three-year unadjusted and adjusted clinical outcomes stratified according to left ventricular ejection fraction
status and revascularization strategy
Clinical outcomes PCI frequency,
n (%)
CABG frequency,
n (%)
Unadjusted
HR (95% CI), P-value
Pinteraction Adjusted
HR (95% CI)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Death, stroke or MI
HFrEF 11 (29.3) 8 (27.6) 1.04 (0.46–2.35), 0.90 1.05 (0.42–2.61)
HFmrEF 11 (16.2) 12 (15.0) 0.96 (0.38–2.38), 0.92 0.90 1.06 (0.40–2.80)
Preserved LVEF 113 (14.6) 113 (14.5) 0.99 (0.76–1.28), 0.89 1.05 (0.79–1.38)
Death, stroke, MI or IDR
HFrEF 12 (31.9) 9 (31.0) 1.22 (0.59–2.52), 0.82 1.18 (0.53–2.66)
HFmrEF 15 (22.1) 14 (17.4) 0.92 (0.39–2.19), 0.59 0.78 1.03 (0.41–2.56)
Preserved LVEF 173 (22.4) 147 (18.9) 1.18 (0.95–1.47), 0.16 1.24 (0.98–1.56)
All-cause death
HFrEF 7 (18.6) 6 (20.7) 0.63 (0.21–1.87), 0.78 0.53 (0.16–1.81)
HFmrEF 5 (7.4) 9 (11.5) 0.85 (0.29–2.54), 0.40 0.20 0.77 (0.23–2.55)
Preserved LVEF 57 (7.4) 39 (5.0) 1.47 (0.98–2.20), 0.08 1.50 (0.98–2.31)
Cardiovascular death
HFrEF 5 (13.5) 5 (17.8) 0.38 (0.08–1.88), 0.62 0.15 (0.02–1.28)
HFmrEF 2 (3.0) 6 (7.8) 0.73 (0.21–2.51), 0.22 0.26 0.70 (0.18–2.81)
Preserved LVEF 29 (3.8) 23 (3.0) 1.27 (0.73–2.19), 0.40 1.40 (0.79–2.48)
Stroke
HFrEF 2 (5.5) 1 (4.2) 0.75 (0.13–4.49), 0.74 1.43 (0.19–10.69)
HFmrEF 2 (3.0) 3 (3.8) 1.49 (0.13–16.39), 0.77 0.49 -
Preserved LVEF 14 (1.9) 23 (3.0) 0.61 (0.31–1.19), 0.14 0.67 (0.34–1.32)
MI
HFrEF 3 (8.9) 3 (10.3) 1.00 (0.34–2.97), 0.62 0.95 (0.29–3.19)
HFmrEF 6 (9.0) 7 (8.7) 0.69 (0.14–3.41), 0.99 0.78 1.02 (0.17–6.29)
Preserved LVEF 62 (8.1) 65 (8.4) 0.95 (0.67–1.35), 0.79 0.99 (0.69–1.44)
Repeat revascularization, any
HFrEF 4 (11.9) 2 (7.5) 2.30 (0.58–9.19), 0.68 1.91 (0.45–8.10)
HFmrEF 6 (9.3) 3 (3.8) 1.43 (0.26–7.82), 0.37 0.96 2.77 (0.31–25.02)
Preserved LVEF 100 (13.2) 61 (8.1) 1.68 (1.22–2.30), 0.001 1.72 (1.23–2.39)
Ischaemia-driven revascularization
HFrEF 4 (11.9) 2 (7.5) 2.30 (0.57–9.18), 0.68 1.86 (0.44–7.88)
HFmrEF 6 (9.3) 3 (3.8) 1.43 (0.26–7.82), 0.37 0.95 2.82 (0.31–25.56)
Preserved LVEF 98 (12.9) 60 (8.0) 1.67 (1.21–2.30), 0.002 1.72 (1.23–2.40)
CABG, coronary artery bypass grafting; CI, confidence interval; HFmrEF, heart failure with mid-range ejection fraction; HFrEF, heart failure with reduced ejection fraction;
HR, hazard ratio; IDR, ischaemia-driven revascularization; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary intervention.
The event rates are Kaplan–Meier estimates (n events) with unadjusted and adjusted HR and 95% CI. A full multivariable Cox proportional hazards model using was
constructed to provide adjusted outcomes for the primary and secondary endpoints. Significance levels of 0.10 for both addition and removal from the model were used.
Adjusted models include the following covariates: age, sex (female), body mass index >30 kg/m2, medically treated hypertension, hyperlipidaemia and diabetes, history of MI,
history of stroke or transient ischaemic attack, peripheral vascular disease, carotid artery disease, chronic obstructive pulmonary disease, creatinine >200 μmol/L, recent MI,
history of anaemia, diffuse or small vessel disease, LVEF (as continuous variable), unstable angina, SYNTAX score (as continuous variable), New York Heart Association class
< II, and revascularization strategy (PCI vs. CABG).
clinical outcomes after PCI and CABG are limited, especially in
those patients with left main disease, a strength of the present
study is that it provides important insights into clinical outcomes
during 3-year follow-up in this high-risk patient population. These
insights can aid clinical decision making in determining the optimal
treatment strategy in such a specific patient population requiring
revascularization.
In the overall cohort, patients with HFrEF or HFmrEF had a sig-
nificantly more complex cardiovascular risk profile, compared with
those with preserved LVEF. The detrimental cardiovascular risk
profile especially in patients with HFrEF and LMCAD, in concert
with less viable myocardium, likely drives the increased all-cause ..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
. death rate in this specific subgroup.12,13 While no significant inter-
actions were noted between clinical outcomes 3 years after PCI
and CABG as a function of LVEF, patients with impaired LVEF
(HFrEF and HFmrEF) experienced a longer post-operative hospital
stay after CABG due to more frequent post-operative arrhythmias
and renal failure. In contrast, post-PCI complications and length
of stay were not significantly increased in patients with impaired
LVEF. The clinical outcomes in patients with HFmrEF were essen-
tially similar to the outcomes in patients with preserved LVEF;
findings that contribute to the better understanding of the impact
of heart failure and the preferred treatment modalities in those
patients with LMCAD and LVEF 40–49% and >50%.14,15 Moreover,
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 2 The influence of Left Ventricular Ejection Fraction (LVEF) on all-cause death at 3 years in patients undergoing left main coronary
artery revascularization by either Percutaneous Coronary Intervention (PCI) versus Coronary Artery Bypass Grafting (CABG). CI, confidence
interval.
Figure 3 Three-year primary endpoint after percutaneous coronary intervention (PCI) vs. coronary artery bypass grafting (CABG) in patients
with heart failure with reduced, mid-range and preserved left ventricular ejection fraction (LVEF). Kaplan–Meier estimates of the composite
primary endpoint of all-cause death, stroke, or myocardial infarction (MI) after PCI vs. CABG in patients with heart failure with reduced (A),
mid-range (B) and preserved LVEF (C). P-values were generated by the log-rank test. CI, confidence interval; HR, hazard ratio.
all peri-procedural outcomes should be considered along with the
potential short- and long-term clinical benefits of both revascular-
ization strategies in patients with impaired LVEF during structured
multidisciplinary heart team meetings.
No treatment interactions were observed between PCI and
CABG according to baseline LVEF status for 3-year outcomes.
Nonetheless, impaired LVEF (<50%) was strongly associated with
3-year all-cause death in the overall cohort. To date, conflict-
ing evidence has been published on the preferred revascular-
ization modality in patients with CAD and impaired LVEF, with
limited randomized data to provide guidance. The observational
CREDO-Kyoto PCI/CABG Registry Cohort 2 (LVEF ≤50% vs.
LVEF >50%) reported that PCI in patients with impaired LVEF was
associated with higher rates of all-cause death after 5 years com-
pared to CABG (33.2% vs. 23.4%; P< 0.01).16 The observational,
propensity-matched analysis by Nagendran et al.17 (n = 1738) .
..
..
..
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..
..
..
..
..
..
..
..
.. showed lower rates of major adverse cardiac and cerebrovascu-
lar events and improved 5-year survival with CABG compared
with PCI in patients with diabetes and impaired LVEF (35–49%
and <35%). Nonetheless, the largest pooled analysis of individ-
ual patient-level data from 11 randomized trials found no inter-
action for mortality between treatment strategy (PCI vs. CABG)
and different LVEF cut-off values (<30%, 30–49% and ≥50%;
Pinteraction = 0.65).18
Finally, in the present study the rate of the composite of death,
stroke, or MI at 3 years was significantly higher in patients with
HFrEF (28.3%) compared with those patients with HFmrEF (15.7%)
or preserved LVEF (14.5%) (P = 0.02) (Figure 1A). This finding was
driven by an increased rate of all-cause death and cardiovascular
death in those patients whom are at higher-risk for adverse events
(e.g. patients with HFrEF). Moreover, in a smoothing spline analysis,
the risk of mortality continued to increase when LVEF decreased
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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below 50%. Nonetheless, no significant differences in clinical out-
comes were found between CABG or PCI in patients with LVEF
<40% at 3-year follow-up. The propensity-matched analysis by Shah
et al.19 (n = 134) reported that patients with coronary artery dis-
ease and LVEF <30% experienced an increased risk of mortality
when undergoing PCI vs. CABG at 8-year follow-up (multivariable
adjusted HR 3.29, 95% CI 1.78–6.10; P< 0.001). However, only
32% of patients in the study by Shah et al. had LMCAD, with the
majority having three-vessel disease. Longer-term follow-up from
the EXCEL trial is required to determine if differences in survival
between the PCI and CABG groups might emerge over time.
Limitations
Although the present analysis was pre-specified, the number of
patients with impaired LVEF was modest, especially those with
HFrEF (n = 74), limiting statistical interaction testing. Further-
more, the EXCEL trial excluded patients with high site-assessed
SYNTAX scores (>32), and thus the present results might not
apply to the particularly high-risk group with more complex CAD
in whom CABG is considered standard of care. Finally, patient
follow-up in the EXCEL trial is prolonged up to 5 years; however,
even this follow-up duration may not be long enough to determine
a potential benefit of either revascularization strategy.
Conclusions
At 3-year follow-up in the EXCEL trial, the composite rate of
death, stroke, or MI was significantly higher in patients with HFrEF
compared with HFmrEF or preserved LVEF, driven by an increased
rate of all-cause death. No significant differences in clinical out-
comes after PCI vs. CABG were observed among patients with
HFrEF, HFmrEF and preserved LVEF. Prolonged follow-up could
provide important insights on differences in clinical outcomes that
might emerge over time.
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